In addition, a phase I trial of samotolisib (dual PI3K-mTOR inhibitors) in combination with cyclin dependent kinase (CDK) inhibitors in ER+ breast cancer patients is ongoing [88]. The gene discussed is PIK3CA; the disease is breast carcinoma.